No need to charge more to make more. Many patients and doctors elect not to use it due to its marginal results, poor safety and high cost. If/when B-OM receives approval, its safety and efficacy will make it part of the standard of care for treatments likely to result in mucositis, perhaps tripling or even quadrupling (or more) the number of patients who receive Kepivance.
News 
Market Data 
Discover 
